Geron Corp (GERN)

[Leronlimab4DaWin]

It is effectively the same drug as five years ago that has failed multiple different safety profiles.

Look at the investor base: all retail! The only institutional/sophisticated investors that show are up boxed longs.

So let's think, what do you know about the drug that the PhD/MDs running these HFs that are short don't?

Let's ask it in a different way: Why are you not running $2B biotech fund like these guys? Is it bc you just don't want to or is it bc their performance crushes yours bc they are professional investors?

Looking forward to hearing those comments. And before you say "they are manipulators." see my last post about companies that fight short sellers or blame short sellers and their long term performance...